FDA approved psychoactive medication for Children

Fluoxetine for Pediatric Patients US FDA Approved for Pediatric Use Major depressive disorder (fluoxetine, ages 8 and older) Obsessive compulsive disorder (fluoxetine, ages 7 and older) Bipolar depression [in combination with olanzapine (Symbyax), ages 10 and older] Off-Label for Pediatric Use But Approved in Adults Panic disorder (fluoxetine, fluoxetine weekly) Premenstrual dysphoric disorder (Sarafem) Bulimia […]

Antidepressants medication: they work but what to do with side effects?

Antidepressant medications can be a godsend for people struggling with the dark mantle of depression. Yet like all drugs, they can cause side effects, which is why it’s important to be aware of any changes in your body when you begin any new medication. If you have any uncomfortable or worrisome antidepressant side effects, tell […]

SWOT Analysis -To Run your clinic or hospital

SWOT analysis (alternatively SWOT Matrix) is an acronym for strengths, weaknesses, opportunities, and threats and is a structured planning method that evaluates those four elements of an organization, project or business venture. A SWOT analysis can be carried out for a company, product, place, industry, or person. It involves specifying the objective of the business venture or project and identifying the internal […]

Paliperidone (Invega®)

Paliperidone extended-release (US brand name Invega® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications 1. Treatment of schizophrenia in adults and adolescents (ages 12-17) 2. Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. Dosage A. Schizophrenia (adults) Initial: 6 mg/day Recommended: 3 – 12 mg/day […]

3-month paliperidone palmitate (Invega Trinza®)

Paliperidone palmitate (Invega Trinza®) is an extended-release injectable second-generation (“atypical”) antipsychotic which can be administered once every 3 months. Here is basic information about this medication. FDA-Approved Indication Schizophrenia after adequate treatment with 1-month paliperidone palmitate extended-release (Invega Sustenna®) for at least four months. Dosage The dose of 3-month paliperidone palmitate (Invega Trinza®) will depend on the last […]

Extended Release Olanzapine (Zyprexa Relprevv®)

Extended Release Olanzapine (Zyprexa Relprevv®) is a long-acting, second-generation (atypical), injectable antipsychotic. Here is basic information about this medication. FDA-approved indications Schizophrenia Dosage Recommended dosing of extended release olanzapine based on correspondence to oral olanzapine doses A. First 8 weeks of treatment a) Target oral dose 10 mg/day: 210 mg/2 weeks or 405 mg/4 weeks b) Target oral […]